BDPT: BioAdaptives, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.36
Enterprise Value ($M) 1.56
Book Value ($M) -1.46
Book Value / Share -0.16
Price / Book -0.93
NCAV ($M) -1.46
NCAV / Share -0.16
Price / NCAV -0.93

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -15.33
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.14
Current Ratio 0.15

Balance Sheet (mrq) ($M)
Current Assets 0.26
Assets 0.26
Liabilities 1.73
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.01
Operating Income -0.58
Net Income -0.90
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.25
Cash from Investing 0.00
Cash from Financing 0.33

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
10-22 13D Azuna Health LLC 100.00
10-22 13D Keener James 100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K
2024-11-19 10-Q Form 10-Q
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number 000-54949
2024-05-17 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number 000-54949

(click for more detail)

Similar Companies
AXIM – AXIM Biotechnologies, Inc. AZNCF – AstraZeneca PLC
BCHMF – Bachem Holding AG BEIGF – BeiGene, Ltd.
BGMD – BG Medicine, Inc.


Financial data and stock pages provided by
Fintel.io